Systemic Treatment of Early-stage Hormone Receptor Positive and HER-2 Negative Early Breast Cancer According to Clinical and Genomic Risk: A Survey of Members of Korean Breast Cancer Society (PART II)
Journal of Breast Disease · 30.06.2026 · 14 (1) · 67-76
DOI: 10.14449/jbd.2026.14.1.67 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Breast Disease, online erschienen am 30.06.2026. Verfasst von Eun Young Kim. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Purpose
This study aimed to investigate how Korean breast cancer specialists integrated these clinicopathological variables into diverse clinical scenarios and also evaluated the degree of concordance with major international clinical trials and consensus recommendations.
Methods
A web-based survey was conducted among the members of the Korean Breast Cancer Society between August and October 2025. The survey consisted of seven clinical scenarios, with three questions for each scenario. Each question was designed to alter only a single variable such as patient age, tumor size, nodal status, 21-gene recurrence score (RS), or histological subtype, to independently assess its influence on treatment decision-making. Respondents selected their preferred management options from among upfront surgery, neoadjuvant chemotherapy, multigene assay testing, or adjuvant systemic therapy. Consensus was defined as agreement by more than 60% of respondents regarding a single treatment option.
Results
A total of 70 breast cancer specialists participated, of whom 97.1% were breast surgeons. RS-based treatment decisions closely reflected the findings of the RxPONDER trial, with postmenopausal patients demonstrating a 4- to 10-fold higher rate of chemotherapy omissions than premenopausal patients within the same RS range. Regarding cT2N1 disease, a higher proportion of respondents in the younger age group preferred neoadjuvant chemotherapy (45.7% in 65-year-old patients vs. 82.9% in 34-year-old patients). In pT1N0 disease, a higher proportion selected multigene assays as tumor size increased (pT1a, 25.7% to pT1c, 92.8%). In pT3N1 disease, histological subtype was associated with differing treatment preferences, despite identical anatomical stage and molecular characteristics.
Conclusion
As this survey was conducted among physicians, the findings reflected self-reported practice patterns rather than patient outcomes. The reported response patterns among Korean breast cancer specialists appeared to be consistent with the findings of major clinical trials such as RxPONDER and TAILORx, as well as the recommendations of the St. Gallen 2021 International Consensus.
Zitieren
APA
Kim, E. Y. (2026). Systemic Treatment of Early-stage Hormone Receptor Positive and HER-2 Negative Early Breast Cancer According to Clinical and Genomic Risk: A Survey of Members of Korean Breast Cancer Society (PART II). Journal of Breast Disease, 14(1), 67-76. https://doi.org/10.14449/jbd.2026.14.1.67
Vancouver
Kim EY. Systemic Treatment of Early-stage Hormone Receptor Positive and HER-2 Negative Early Breast Cancer According to Clinical and Genomic Risk: A Survey of Members of Korean Breast Cancer Society (PART II). Journal of Breast Disease. 2026;14(1):67-76. doi:10.14449/jbd.2026.14.1.67
BibTeX
@article{Kim2026,
author = {Kim, Eun Young},
title = {Systemic Treatment of Early-stage Hormone Receptor Positive and HER-2 Negative Early Breast Cancer According to Clinical and Genomic Risk: A Survey of Members of Korean Breast Cancer Society (PART II)},
journal = {Journal of Breast Disease},
year = {2026},
volume = {14},
number = {1},
pages = {67--76},
doi = {10.14449/jbd.2026.14.1.67}
}
EUVIMED